Figure 2.

Percentage of volunteers endorsing specific answers on the Persisting Effects Questionnaire completed 2 months following the methylphenidate (Methp) and psilocybin (Psil) sessions (n=29), and again retrospectively for psilocybin at the 14-month follow-up (N=36). For ratings of personally meaningful and spiritually significant (top two panels), the data are the percentage rating “among the top 5” or “the single most.” For ratings of increased well-being or life satisfaction, the data are the percentage rating “increased moderately” or “increased very much.” For ratings of positive behavioral change, the data are the percentage rating “moderate”, “strong”, or “extreme.” Asterisks show significant differences (p<.05, z-test of proportions, n=29 at each assessment) from the methylphenidate 2-month assessment; there were no significant differences between the psilocybin 2-month condition and the psilocybin 14-month follow-up assessment. For the methylphenidate results, the data presented are from the first methylphenidate session for the 5 subjects who received methylphenidate on two sessions and who completed this questionnaire.